Low Sexual Desire Around Menopause

A useful consultation asks whether desire has changed, whether sex is painful, and whether the change causes distress. Desire may vary by situation or develop after intimacy begins. The goal is to understand your experience and what you would like to improve, without imposing a frequency or performance target.

Describe when the change began, whether it occurs across situations, and any dryness, burning, or pain. Include sleep, mood, fatigue, relationship concerns, previous treatment, and medicines. Some antidepressants and other prescriptions can affect sexual function. Do not stop them abruptly; discuss alternatives with the prescriber.

Hypoactive sexual desire disorder, or HSDD, refers to persistently low desire associated with significant distress after appropriate assessment. A testosterone blood result cannot diagnose it. The ISSWSH guideline recommends assessing psychological, relationship, medication, and medical factors before selecting treatment.

Vaginal and vulval dryness can make intimacy uncomfortable and reduce the wish to repeat a painful experience. Lubricants during sex and regularly used vaginal moisturizers can help. Local vaginal estrogen is an option for menopause-related genitourinary symptoms, selected after reviewing history and preferences.

Persistent pain, bleeding after sex, unusual discharge, or a skin change needs assessment. Infection, pelvic-floor problems, skin conditions, and other causes may require different care. You should not have to continue an activity that hurts while waiting for treatment.

Sleep treatment, depression or anxiety care, medication review, and counseling for relevant relationship or sexual concerns can also help. Systemic HRT may be appropriate for other troublesome menopause symptoms, but improved desire is not guaranteed.

Testosterone should be considered after a full assessment of contributors. Treatment for women is off-label in the US, with carefully adjusted transdermal formulations when used. Long-term safety has not been established. ISSWSH recommends against compounded testosterone and against pellets, injections, or oral preparations for this purpose.

Baseline and follow-up testosterone levels help prevent excessive dosing; they are not used to diagnose HSDD. The guideline recommends a check three to six weeks after starting and periodic monitoring once stable. New acne, facial hair, scalp thinning, or voice changes needs review. Treatment should be reconsidered if meaningful benefit is absent by six months.

The December 2025 US label expanded Addyi to women under 65 with acquired, generalized HSDD. The low desire must cause marked distress or interpersonal difficulty and must not be due to another medical or psychiatric condition, relationship problems, or a drug effect. This includes eligible postmenopausal women; older information describing it as only for premenopausal women is outdated.

Addyi is taken daily at bedtime and can cause sedation, low blood pressure, or fainting. It is contraindicated with liver impairment and moderate or strong CYP3A4 inhibitors. Alcohol timing has strict instructions: wait at least two hours after one or two standard drinks; skip the dose that evening after three or more. Avoid alcohol after the bedtime dose until the next day.

A prescriber should review the full medication list and explain these instructions before treatment. The label directs stopping after eight weeks if there is no improvement. Follow-up should assess your own desire and distress, as well as adverse effects and whether the treatment remains suitable.